Pharmacokinetics of Atropine Oral Gel

This is an interventional treatment trial for Cerebral Palsy focused on measuring Pharmacokinetics, Cerebral Palsy, Sialorrhea, Atropine sulfate gel Read More

Inclusion Criteria:

1. Provide written informed consent and authorization.
2. Study participants must be able to complete consent, and all study evaluations written in the English language.

Exclusion Criteria:

1. Female subjects who are pregnant or nursing at the time of screening
2. Chemotherapy or radiotherapy treatment within the last three months

3. Severe renal impairment defined as estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 calculated using the CKD-EPI creatinine equation:

   eGFR (mL/min/1.73 m2) = 141 x min(Scr/k, 1)α x max(Scr/k,1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black]

   Where,

   1. k=0.7 if female
   2. k=0.9 if male
   3. α=-0.329 if female
   4. α=-0.411 if male
   5. min=The minimum of Scr/k or 1
   6. max=The maximum of Scr/k or 1
   7. Scr = serum creatinine (mg/dL)

4. Acute hepatitis in the prior 6 months, a prior history of cirrhosis, acute hepatic failure, or acute decompensation of chronic hepatic failure; and/or any of the following blood test results, for any individual, when assessed for eligibility:

   1. Bilirubin > 3 x upper limit of normal (ULN). [ULN for bilirubin = 1.4 mg/dL]
   2. Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) > 3 x ULN values used by the laboratory performing the test. [ULN for AST = 40 U/L, ULN for ALT = 60 U/L]
   3. Alkaline phosphatase (ALP) > 3 x ULN [ULN for ALP = 126 U/L)
5. Deforming lesions of the oral cavity
6. Previous head and/or neck radiotherapy
7. Patients with a history of hypersensitivity reaction towards atropine and/or Carbopol 980 NF or any carbomers
8. Patients with heart conditions such as congenital heart disease, heart failure, coronary heart disease, myocardial infarction, and arrhythmia
9. Patients with acute glaucoma that may be exacerbated with atropine administration.
10. Patients with partial pyloric stenosis or other diseases related to gastrointestinal obstruction.
11. Patients diagnosed with urinary retention
12. Treatment with any other investigational drug during the 30 days prior to enrollment into the study
13. Patients receiving anticholinergic medications at baseline.
14. Patients who are receiving immunosuppression
15. Patients who are actively being treated for an infection
16. Patients with a history of salivary gland obstruction or stones
17. Patients with a history of chronic lung disease or chronic obstructive pulmonary disease (COPD)
18. Patients with an artificial airway (tracheostomy)
19. Patient taking monoamine oxidase inhibitors